Tractivus, a client of ABG’s, has recently been awarded the Seal of Excellence for SMEs within the Horizon 2020 framework for research and innovation by the European Commission. This Award…
Peptomyc has recently been on the news for having completed preclinical validation studies of Omomyc as effective and tolerable against notoriously difficult-to-treat lung cancer subtype. Peptomyc has just published a…
Spherium Biomed presented last Saturday at the EADV Congress in Paris the results of the clinical trial Cyclatop (NCT02865356) to investigate the safety, tolerability, pharmacokinetics and efficacy of SP14019 (Cyclosporine A 5% topical spray) across…
The Independent Association of Young Entrepreneurs of Catalonia (AIJEC) has awarded the Award for the Best Business Initiative of its 25th edition to Peptomyc. Peptomyc is a spin-off of the Vall d’Hebron Institute of…
Spherium Biomed announced on May 17, 2018 that it has obtained positive results with its new drug Mucomel® in a phase I/IIa clinical trial for the prevention and treatment of oral…
This phase IIa clinical study in paediatric and adult patients with mild to moderate atopic dermatitis is designed as a proof-of-concept, multi-centre, randomised, double-blind, vehicle-controlled study with intra-individual comparison of…
Spherium Biomed has recently signed a licensing agreement with Simini Technologies from Ontario (Canada) to develop veterinarian applications based on the Spherium’s proprietary topical cyclosporine (SP14019). Simini will develop its lead…
Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), receives approval by the European Commission of Ciclopirox as…
©2021 ABG Intellectual Law S.L. All Rights Reserved
